#Germany #Fresenius Medical Care #Bad Homburg #5008X CAREsystem #FME25+ Program

Fresenius Medical Care Achieves Extraordinary Earnings Growth in 2025

Fresenius Medical Care has successfully closed a year characterized by remarkable financial performance, marked by a 27% increase in operating income for 2025. The company reached the upper end of its financial outlook, resulting in a substantial margin improvement to 11.3%, a notable achievement amidst a challenging market landscape.

In 2025, Fresenius Medical Care experienced robust organic revenue growth of 8%. This performance was primarily driven by significant contributions from all operating segments and an exceptional fourth quarter that propelled overall financial results. The company's operating income increased significantly, achieving a yearly total income growth of 27%, in line with its mid-term financial objectives placed for 2025.

Helen Giza, the Chief Executive Officer of Fresenius Medical Care AG, expressed satisfaction with the year’s results, highlighting the company's transformation over the last three years. "Our achievements reflect our disciplined approach towards operational and financial excellence—delivering both revenue and operating income growth at the upper end of our forecasts despite the prevalent market adversities," she stated.

For the fourth quarter, revenue stabilized at €5,070 million, with organic growth reported at 8%. The company also recorded significant year-over-year growth in operating income, rising by 129% to €594 million, showcasing an operating income margin of 11.7%.

The strong financial performance, including an 82% hike in reported net income, reflects the impact of steady business growth and several efficiency initiatives implemented under the FME25+ transformation program. The program has led to a cumulative sustainability saving of €804 million, with a projected €150 million additional savings expected by the end of 2027.

Fresenius Medical Care has committed to continuous development and enhancement of its operations. Looking ahead to 2026, the company remains ambitious, planning to expand its innovative 5008X CAREsystem across the United States on a large scale, which will enhance access to high-volume hemodiafiltration for patients.

Moreover, the company set its sights on maximizing profitability while making crucial investments that prepare it for future challenges, including navigating regulatory obstacles. Forecasts indicate a consistent level of operating income is likely to be maintained in 2026, despite facing potential headwinds.

As part of its commitment to shareholder returns, Fresenius plans to propose a dividend of €1.49 per share, reflecting a 3% increase from the previous year, alongside an ongoing share buyback program aimed at reinforcing shareholder value. In 2025, the company successfully executed the first tranche of a €1.0 billion share buyback initiative, marking the beginning of a strategic plan to enhance investor confidence and market positioning.

The premier dialysis provider remains focused on enhancing its product offerings while optimizing its portfolio by divesting non-core assets. These strategic moves aim to streamline operations and concentrate efforts on sectors with sustainable growth potential.

In summary, Fresenius Medical Care's remarkable achievements in 2025 indicate a robust foundation for future growth and an unwavering dedication to improving patient care, ensuring that both operational excellence and financial stability remain central to the company’s strategy as it moves into 2026 and beyond. With ambitious aspirations set for 2028 and beyond, Fresenius Medical Care is positioned well to sustain its leadership in the renal care industry.